---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000006"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:44:58.055865+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma secures $15M convertible note from Daewoong and aligns with FDA on Phase 3 migraine trial design

## Summary
- Issues up to $15M senior secured convertible notes to Daewoong; first $5M tranche closes within 10 days, second $10M subject to license amendment.
- Terminates forward purchase agreements with ACM and Polar; retains ~3.1M shares each, up to $1.5M liquidated damages for registration failures.
- FDA confirms primary endpoint (change in mean monthly migraine days over weeks 13-24) for Phase 3 episodic and chronic migraine programs.
- Interim analysis of ongoing Phase 2 chronic migraine study now planned; data expected Q2 2024, complete top-line data on track for Q3 2024.
- ABP-450 Phase 2 chronic migraine study enrolled 492 patients; will use patented injection paradigm with fewer injections than current treatment.

## SEC filing metadata
- accession: 0001837607-24-000006
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/aeon-20240318x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000006
- JSON: https://secwatch.observer/filing/0001837607-24-000006.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000006.txt

## Key facts
- Debt Financings
  AEON Biopharma, Inc. incurred convertible notes of $15.0 million with Daewoong Pharmaceutical Co., LTD. at 15.79% maturing three years from the funding date.
  - Instrument: convertible notes
  - Principal: $15.0 million
  - Counterparty: Daewoong Pharmaceutical Co., LTD.
  - Rate: 15.79%
  - Maturity: three years from the funding date
  - Event: incurrence
  source text: On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm
- Material Agreements
  AEON Biopharma, Inc. entered into Subscription Agreement with Daewoong Pharmaceutical Co., LTD. valued at $15.0 million (effective 2024-03-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Daewoong Pharmaceutical Co., LTD.
  - Value: $15.0 million
  - Effective: 2024-03-19
  source text: On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.